ArticleBMJ open2017
Cohort profile: the Emory Cardiovascular Biobank (EmCAB).
Article in BMJ open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 37 citations in OpenAlex.
- Soluble Urokinase Plasminogen Activator Receptor (suPAR) Mediates the Impact of Diabetes on Adverse Outcomes in Coronary Artery Disease.Diabetes care · 2026Article
- Lipoprotein(a) Levels and Adverse Outcomes in Heart Failure.Journal of cardiac failure · 2026Article
- Metabolic Signatures of Air Pollution and Major Adverse Cardiovascular Events in Patients Undergoing Cardiac Catheterization.JACC. Advances · 2026Article
- Effects of Exposure to Ambient Air Pollution on Human Metabolome in Patients with Coronary Artery Disease.Environmental science & technology · 2025Article
- Cardiac allograft vasculopathy mediates the relationship between vitamin D deficiency and cardiovascular mortality following heart transplantation.American heart journal · 2025Article
- Employment status as a predictor of adverse outcomes in patients with coronary artery disease.American journal of preventive cardiology · 2025Article
- The Impact of Changes in Depression on Cardiovascular Outcomes in Patients With Coronary Heart Disease.JACC. Advances · 2024Article
- Patients With Nonobstructive Coronary Artery Disease and Chest Pain: Impact of Obesity and Depressive Symptoms.Journal of the American Heart Association · 2024Article
- N terminal pro-brain natriuretic peptide level and benefits of chronic total occlusion revascularization.International journal of cardiology · 2024Article
- Circulating Progenitor Cells and Coronary Collaterals in Chronic Total Occlusion.International journal of cardiology · 2024Article
- Soluble urokinase Plasminogen Activator Receptor (suPAR) mediates the effect of a lower education level on adverse outcomes in patients with coronary artery disease.European journal of preventive cardiology · 2024Article
- Long-Term Outcomes in Patients With Chronic Total Occlusion.The American journal of cardiology · 2024Article
- Vitamin D Deficiency, Inflammation, and Diminished Endogenous Regenerative Capacity in Coronary Heart Disease.JACC. Advances · 2024Article
- High sensitivity troponin I as a biomarker for cardiac allograft vasculopathy: Evaluation of diagnostic potential and clinical utility.Clinical transplantation · 2024Article
- Immune Activation Mediates the Association of Advanced Hepatic Fibrosis With Adverse Outcomes in Patients With Coronary Artery Disease.Journal of the American Heart Association · 2023Article
- High Sensitivity Troponin Level and Benefits of Chronic Total Occlusion Revascularization.Journal of the American Heart Association · 2023Article
- Circulating progenitor cells and outcomes in patients with coronary artery disease.International journal of cardiology · 2023Article
- Soluble Urokinase Plasminogen Activator Receptor Levels and Outcomes in Patients with Heart Failure.Journal of cardiac failure · 2023Article
- Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations.JAMA cardiology · 2022Article
- Usefulness of Restless Legs Symptoms to Predict Adverse Cardiovascular Outcomes in Men With Coronary Artery Disease.The American journal of cardiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe Emory Cardiovascular Biobank (EmCAB) is an ongoing prospective registry of patients undergoing cardiac catheterisation, which was established to identify novel factors associated with the pathobiological process and treatment of cardiovascular disease.
participantsIndividuals aged 18 years and older undergoing cardiac catheterisation at three Emory Healthcare sites in Atlanta are asked to participate in this prospective registry. Around 95% agree to participate. Around 7000 unique patients have been enrolled. The current data set contains detailed phenotyping, patient outcomes, genomics, protein biomarkers, regenerative markers, transcriptomic analysis, metabolomics profiling and longitudinal follow-up for adverse cardiovascular outcomes. FINDINGS TO DATE: Thus far, the EmCAB has approximately 3000 major cardiovascular events. About 48% of the EmCAB participants have more than 5 years of follow-up. It is a great resource for discovery of novel predictive factors for cardiovascular disease outcomes, including genomics, transcriptomics, protein biomarkers, oxidative stress markers and circulating progenitor cells. Several circulating inflammatory markers have shown to improve risk prediction metrics beyond standard risk factors. FUTURE PLANS: Future integrative -omics analyses will provide the cardiovascular research community opportunities for subsequent mechanistic confirmation studies, which will promote the development of effective personalised therapy that leads to clinical care tailored to the individual patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.